MyoKardia Inc. (NASDAQ:MYOK) fell 8% during trading on Friday . The stock traded as low as $20.20 and last traded at $20.47, with a volume of 117,206 shares trading hands. The stock had previously closed at $22.25.
Several brokerages recently commented on MYOK. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Credit Suisse Group AG restated a “buy” rating and set a $20.00 target price (up previously from $16.00) on shares of MyoKardia in a research report on Tuesday, July 12th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of MyoKardia in a research report on Thursday, May 12th. BMO Capital Markets began coverage on MyoKardia in a research report on Wednesday, July 20th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, Cowen and Company restated a “buy” rating on shares of MyoKardia in a research report on Friday, May 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. MyoKardia has a consensus rating of “Buy” and an average target price of $23.50.
The stock’s market cap is $541.75 million. The stock has a 50-day moving average of $19.40 and a 200 day moving average of $13.66.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/09/myokardia-inc-myok-trading-down-8.html
MyoKardia (NASDAQ:MYOK) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. MyoKardia had a negative return on equity of 62.91% and a negative net margin of 222.21%. The firm had revenue of $3.55 million for the quarter, compared to the consensus estimate of $3.55 million. The firm’s quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts expect that MyoKardia Inc. will post ($1.50) EPS for the current year.
MyoKardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for MyoKardia Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MyoKardia Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.